PlanetMedicines

The originally published report (1) presented results from multiple studies performed in our laboratory over a span of approximately 2 years demonstrating that a novel systemic dose regimen of what we believed was MDMA produced severe dopamine neurotoxicity in two species of nonhuman primates, in addition to the previously reported serotonin neurotoxicity (3–6). Subsequent to the publication of those findings, we were unable to extend the dopamine neurotoxicity to orally administered doses. Multiple subsequent attempts to reproduce the original findings with systemically administered doses of MDMA identical to those used in the original study were also unsuccessful, under a variety of laboratory conditions.

This article demonstrates that TESCREALism is a driving force in major segments of the psychedelic pharmaceutical industry, where it is influencing the design of extractive systems that directly contradict the field's world-healing aspirations. These findings contribute to a developing subfield of critical psychedelic studies, which interrogates the political and economic implications of psychedelic medicalization.

“There may be potential in the future to safely deliver a DMT-based treatment to patients on SSRIs that do not adequately relieve their depression symptoms. Moreover, the marked antidepressant effect seen in the SSRI patient cohort indicates the potential for a combination treatment.”